Eli Lilly telehealth deals to prevent sale of compounded GLP-1s
Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ensuring that compounded versions of its GLP-1 weight-loss drugs are not being sold on these sites.
Yahoo Finance senior health reporter Anjalee Khemlani sheds more light on this and compares other GLP-1 manufacturers' telehealth deals.
Also watch Anjalee Khemlani's coverage of US Health Secretary Robert F. Kennedy, Jr.'s decision to remove all 17 members of the Centers for Disease Control and Prevention's (CDC) vaccine advisory panel.
To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Hairstylists and medical expert confirm temporary hair loss affecting Ozempic users
Side effects from GLP-1s can vary — but one lesser-known reported outcome of the popular weight-loss medications is hair loss or thinning. Some hairstylists have confirmed an uptick in clients who complain about losing hair while on weight-loss journeys. This includes Ashley DiMatteo, owner of Ashley Lauren Beauty Lounge in Westchester, New York, and Briana Delvecchio, a color specialist and hairdresser at DiMatteo's salon. The two spoke with Fox News Digital in an on-camera interview (see the video at the top of the article). Is Ozempic Ruining Your Teeth? What To Know About Impact On Dental Health "There has definitely been an increase in clients coming in with hair loss," DiMatteo said, noting that it ranges from gradual to fast, and from thinning out to completely losing hair. Delvecchio agreed that she's had "a few" clients come in reporting thinner and drier hair, which she suspects could be due to weight-loss drugs. Read On The Fox News App The hairstylist, who herself takes a GLP-1 drug, said there may be a few reasons for hair changes — including new medications, vitamin deficiencies and weight loss, which can put stress on the body. Becky Watt, an Ohio hairstylist with more than 20 years of experience, said she has also noticed clients losing hair while taking weight-loss drugs. "I've seen thinning and shedding, and a lot of hair coming out very easily when being washed," she told Fox News Digital. "I have not noticed any bald spots." However, she has had some clients who are taking the medications without any hair loss, Watt added. In a separate interview, Dr. Philip Rabito, an endocrinologist in New York City, explained that this reaction, called telogen effluvium, is a stress response to weight loss that affects the hair follicle. Ozempic, Other Semaglutides Linked To Hair Loss: Here's What To Know The response is only temporary, he noted — the hair will fall out and then grow back once the weight loss stabilizes after a few months. "It's a response to severe physical stress — and weight loss is considered starvation," Rabito said. "It is the rapidity of the weight loss that correlates with the amount of hair loss." Before weight-loss drugs, traditional bariatric surgery would lead to the loss of 70% of excess body weight in about six months, Rabito shared — which was often followed by hair loss within six to nine months. "Your body doesn't understand that this is healthy weight loss — your body thinks it's starving," he reiterated. "It happens to almost everyone, to some people more than others." This Daily Beauty Routine Could Be Ruining Your Hair, Experts Warn Those who lose weight more repetitively are at higher risk of hair loss, Rabito said, as well as those who have an underlying thyroid issue or micronutrient deficiency — typically in iron, B12 or vitamin D. These vitamin deficiencies can worsen as weight loss occurs, so it's important to work with a medical professional to balance these levels, according to the doctor. "From what I have learned from talking to these specific clients, it seems that the clients that are still eating don't have the hair loss," Watt observed. "It seems that my clients who say they don't have any appetite whatsoever are the ones losing the most hair," she went on. "I believe that's possibly due to lack of nutrients and protein, although I'm no doctor." DiMatteo and Delvecchio agreed that they "always" advise their clients to see their doctor for a vitamin level check. "And we will also then taper their hair routine," DiMatteo said. "Basically, less is more during hair loss." The salon owner suggests keeping up with scalp treatment, reducing the use of heat, brushing from the bottom up and avoiding going to bed with wet hair. "Check in with your weight-loss doctor or your endocrinologist prior to coming to us to rule out iron, vitamin D or anything that you're lacking — we need to rule that out before we can help you," Delvecchio said. "Then we'll tell you we need to work on your scalp health; we'll give you shampoo and conditioner that may be a little gentler for your hair." "Scalp stimulation is huge," DiMatteo added. "Rinsing with cool water helps as well. Try not to do harsher treatments in the sense of lightening or coloring — spread it out as much as possible." Rabito noted that losing hair is "part of the game" — he said he always warns his patients before starting their weight-loss journey that this will most likely occur and is a "mark of success." "They're going to lose hair," he said. "It's going to get worse before it gets better." "But as long as you get the vitamins controlled, get them adequately repleted — when the patient plateaus and the weight is stable for a month or two, the body doesn't sense starvation anymore, and the body is less stressed, then the hair grows back better than ever." Watt said she often recommends a hair vitamin to her clients struggling with weight loss. "Diet also has a lot to do with it," she noted. She also recommends using a shampoo and conditioner that are formulated to resist thinning and hair loss, along with a bond-building hair product. Click Here To Sign Up For Our Health Newsletter DiMatteo and Delvecchio assured those who are experiencing hair loss that regrowth does take time, and that there's no need for excessive hair growth treatments. Delvecchio added, "The hair loss is temporary. It's a positive stress, and it's worth it." When previously contacted by Fox News Digital, Novo Nordisk — maker of Ozempic and Wegovy — confirmed that hair loss is an identified risk for semaglutide, and is listed as a side effect in the product information. "In clinical trials of Wegovy, hair loss was reported in 2.5% of Wegovy-treated adult patients versus 1.0% of placebo-treated adult patients," the company spokesperson said at the time. For more Health articles, visit "Hair loss was reported more frequently in patients with greater weight loss (≥20%), suggesting that the events of hair loss were potentially related to the magnitude of weight loss." "Patient safety is of utmost importance to Novo Nordisk," the statement continued. "We are continuously monitoring the safety profile of our products and collaborate closely with authorities to ensure patient safety, including adequate information on hair loss." Melissa Rudy contributed article source: Hairstylists and medical expert confirm temporary hair loss affecting Ozempic users
Yahoo
3 hours ago
- Yahoo
Down 12%, Should You Buy the Dip on Eli Lilly?
Eli Lilly's revenue has soared in recent years thanks to its leadership in the weight loss drug market. The company recently released positive phase 3 data from a potential new addition to that portfolio. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has been a great growth pick for investors over the past few years. The pharma company, thanks to its weight loss drug portfolio, has seen revenue climb in the double digits -- and as a result, the stock has taken off, climbing more than 170% in three years. You may recognize the names of these blockbusters driving Lilly's growth, as they've been widely talked about across the media. Lilly sells tirzepatide, commercialized as Zepbound for weight loss and Mounjaro for type 2 diabetes. Doctors have prescribed either for the weight loss indication, and together, the two drugs generated more than $16 billion in revenue for Lilly last year. On top of this, Lilly has a broad portfolio of drugs targeting a wide range of indications, so this company doesn't rely uniquely on one treatment area -- though the weight loss portfolio has been the focus in recent times due to its performance so far and future prospects. All of this is fantastic, but it has pushed the valuation of this stock higher -- so it resembles that of a tech stock rather than that of a pharmaceutical company. In recent times, though, Lilly has become less expensive, as the stock slipped 12% from a high reached in March. Is Lilly a buy on the dip? Let's find out. So, let's consider what might be ahead for the company's weight loss portfolio. While it may seem as if the growth story is in full bloom right now, there could be a lot more to come down the road -- for two reasons. First, analysts have forecast that the weight loss drug market may reach nearly $100 billion in about five years -- up from about $28 billion today. Second, Lilly's current drugs may represent its very first step in this high-potential market. The company is developing two other candidates that could prove to be even better than current options -- and they're both approaching the finish line. Today, tirzepatide is given in injectable form weekly. The drug, known as a dual GIP/GLP-1 receptor agonist, acts on hormones involved in digestion, and as a result helps regulate appetite and blood sugar levels. The product has been so popular that it was on the market regulator's drug shortage list until Lilly ramped up manufacturing to meet soaring demand. Moving forward, Lilly may offer those aiming to lose weight another even better option: a weight loss drug in pill form. The company's candidate, orforglipron, recently delivered strong efficacy data and a safety profile similar to today's injectables, and Lilly aims to apply for regulatory approval in the weight loss indication by year-end and in the type 2 diabetes indication next year. This potential product could represent significant growth for Lilly because patients may prefer a pill to an injection, and it's easier and cheaper for Lilly to manufacture a pill than medicine in an injection pen format. Lilly also has another weight loss candidate -- retatrutide -- in phase 3 trials, and it acts on not just two but three hormonal pathways, suggesting it may be even more efficacious than current commercialized weight loss drugs. All this means Lilly's weight loss drug-driven growth could be in its early days. And the company has prepared for this, making the biggest-ever pharma manufacturing investment in the U.S. -- this is a commitment of more than $50 billion over the past five years. Of course, Lilly may face some headwinds that could limit the pace of growth. For example, a lack of reimbursement from certain health plans or pricing pressures as rival drugs enter the market represents risks. In fact, these and other concerns prompted Goldman Sachs Research to lower its obesity drug market forecast to $95 billion by 2030 from $130 billion. Still, even considering potential headwinds, Lilly is likely to deliver significant growth from its weight loss drugs in the years to come, especially since it is leading when it comes to innovation -- orforglipron would represent the only weight loss drug of its class in pill format that doesn't come with strict food and water guidelines. So, does this make Lilly a buy today? The stock trades at 37x forward earnings estimates, down from nearly 43x just three months ago. This is expensive for a pharmaceutical company, but Lilly's leadership in the high-growth weight loss market makes it worth this premium. At the same time, like its pharma counterparts, Lilly offers investors the safety of a big pharmaceutical company -- regardless of the economic situation, people need their medicines, and this results in steady revenue for these players. Also, like pharma rivals, Lilly offers investors passive income in the form of dividends. So, the answer to our question, is, yes, Lilly is a buy on the dip, because it gives investors the best of both worlds -- strong growth and safety. And today you can get that on sale. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor's total average return is 998% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool has a disclosure policy. Down 12%, Should You Buy the Dip on Eli Lilly? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
10 hours ago
- Business Insider
Johnson Controls announces $9B increase to share repurchase program
The board of directors of Johnson Controls (JCI) has approved a $9B share repurchase authorization, adding to the $1.1B remaining as of the end of the second fiscal quarter under the share repurchase authorization previously approved in 2021. In implementing share repurchases, Johnson Controls may purchase shares in the open market or through a variety of methods as permitted by applicable securities laws and other legal requirements, including through the use of a Rule 10b5-1 plan, a tender offer or an accelerated share repurchase program or any combination of the foregoing. There exists no obligation under the share repurchase authorization to repurchase any particular amount of shares within any timeframe, and the manner, timing and amount of any purchase will be determined subject to an evaluation of the price of Johnson Controls' shares, general market conditions and other factors. Johnson Controls' authorization to repurchase shares does not have a set expiration date and may be amended, suspended or terminated at any time at Johnson Controls' discretion without prior notice. Johnson Controls currently expects to effect repurchases as redemptions pursuant to Article 3(d) of its Articles of Association.
